**6. Anti-infective medicines**

**6.2. Antibacterials**

**6.2.2. Watch group antibiotics**

---

**Ceftriaxone**

**Indication**

Bacterial infection of joint  
**ICD11 code:** FA10.0

**INN**

Ceftriaxone

**Medicine type**

Chemical agent

**Antibiotic groups**

WATCH

**List type**

Core

**Additional notes**

Do not administer with calcium and avoid in infants with hyperbilirubinaemia.

**Formulations**

Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt) (EML); 500 mg vial powder for injection (as sodium salt)

**EML status history**

First added in 2017 (TRS 1006)  
Changed in 2023 (TRS 1049)

**Sex**

All

**Age**

Also recommended for children

**Age restriction**

> 41 weeks corrected gestational age

**Therapeutic alternatives**

The recommendation is for this specific medicine

**Patent information**

Patents have expired in most jurisdictions  
Read more about patents.  

**Wikipedia**

Ceftriaxone

**DrugBank**

Ceftriaxone

---

**Expert Committee recommendation**

The Expert Committee recommended the inclusion of a new strength, child-friendly dispersible tablet formulation of amoxicillin + clavulanic acid (200 mg + 28.5 mg) as an Access group antibiotic on the core list of the EMLc for treatment of bacterial infections in children – specifically those infections for which amoxicillin + clavulanic acid is already recommended on the EMLc. The Committee noted that the 7:1 ratio of amoxicillin to clavulanic acid is associated with similar efficacy to the 4:1 ratio but has a reduced frequency of gastrointestinal adverse effects. The Committee endorsed the importance of age-appropriate formulations to better meet the dosing needs of children. Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of a new formulation of amoxicillin + clavulanic acid (dispersible tablet 250 mg + 62.5 mg) to the EMLc. - the addition of new strength formulations of cefotaxime (powder for injection: 500 mg; 1 g; 2 g (as sodium) in vial) to the EML and EMLc. - the addition of a new strength formulation of ceftriaxone (powder for injection: 500 mg (as sodium) in vial) to the EML and EMLc. - replacing the oral liquid formulation of clindamycin (oral liquid 75 mg/5 mL) with powder for oral liquid 75 mg/5 mL (as palmitate hydrochloride) on the EML and EMLc. - the addition of new strength formulations of cloxacillin (capsule 250 mg, powder for injection 250 mg (as sodium) and powder for oral liquid 250 mg/5 mL (as sodium) on the EMLc.
<table>
<thead>
<tr>
<th>First choice</th>
<th>Second choice</th>
</tr>
</thead>
<tbody>
<tr>
<td>cloxacillin</td>
<td>cefazolin</td>
</tr>
<tr>
<td>clindamycin</td>
<td>clindamycin</td>
</tr>
<tr>
<td>amoxicillin + clavulanic acid</td>
<td>amoxicillin + clavulanic acid</td>
</tr>
<tr>
<td>cefotaxime</td>
<td>cefotaxime</td>
</tr>
<tr>
<td>ceftriaxone</td>
<td>ceftriaxone</td>
</tr>
</tbody>
</table>